Form D · Other Health Care
Escalante Bioscience, Inc.
San Francisco, CA · CIK 0002023832
Offering snapshot reported May 17, 2024 · SEC filing
- Reported sold
- $6.75M Offering amount: $6.75M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 7, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 17, 2024 | Initial | $6,749,986 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513684
Includes $160,000 in value of cancelled convertible securities.
Source: Form D, filed May 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicholas R Boyd | Director |
| Ching Yun Hsu | Director, Executive |
| April D Schleck | Director, Executive |
| Akshay Tambe | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
953 Indiana St.
San Francisco, CA, 94107
San Francisco, CA, 94107